Patents by Inventor Philip Kusk
Philip Kusk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210128482Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: ApplicationFiled: January 11, 2021Publication date: May 6, 2021Inventors: Philip KUSK, Lars Ulrik WAHLBERG
-
Patent number: 10888526Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: GrantFiled: December 22, 2017Date of Patent: January 12, 2021Assignee: GLORIANA THERAPEUTICS SARLInventors: Philip Kusk, Lars Ulrik Wahlberg
-
Publication number: 20180177736Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: ApplicationFiled: December 22, 2017Publication date: June 28, 2018Inventors: Philip Kusk, Lars Ulrik Wahlberg
-
Patent number: 9884023Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: GrantFiled: August 7, 2015Date of Patent: February 6, 2018Assignee: Gloriana Therapeutics sarlInventors: Philip Kusk, Lars Ulrik Wahlberg
-
Patent number: 9845344Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.Type: GrantFiled: March 30, 2005Date of Patent: December 19, 2017Assignee: HOBA THERAPEUTICS APSInventors: Mette Grønborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Søren Brunak, Lars U. Wahlberg
-
Publication number: 20150335587Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: ApplicationFiled: August 7, 2015Publication date: November 26, 2015Inventors: Philip KUSK, Lars Ulrik WAHLBERG
-
Patent number: 9121037Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: GrantFiled: May 29, 2014Date of Patent: September 1, 2015Assignee: NsGene A/SInventors: Philip Kusk, Lars Ulrik Wahlberg
-
Publication number: 20140377341Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: ApplicationFiled: May 29, 2014Publication date: December 25, 2014Applicant: NsGene A/SInventors: Philip KUSK, Lars Ulrik Wahlberg
-
Patent number: 8741340Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: GrantFiled: January 21, 2010Date of Patent: June 3, 2014Assignee: NsGene A/SInventors: Philip Kusk, Lars Ulrik Wahlberg
-
Publication number: 20120184492Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.Type: ApplicationFiled: December 15, 2011Publication date: July 19, 2012Applicant: NsGene A/SInventors: Mette Grønborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Soren Brunak, Lars U. Wahlberg
-
Publication number: 20120027847Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: ApplicationFiled: January 21, 2010Publication date: February 2, 2012Applicant: NS GENE A/ASInventors: Philip Kusk, Lars Ulrik Wahlberg
-
Publication number: 20120021039Abstract: The present application relates to expression constructs capable of securing correct processing of neuropeptides upon expression in mammalian cells, and to mammalian cells secreting correctly processed peptides. One exemplary peptide is galanin. The application also relates to devices containing neuropeptide secreting cells, which devices may be used for the treatment of epilepsy and other disorders of the nervous system. All references cited herein are incorporated by reference.Type: ApplicationFiled: January 21, 2010Publication date: January 26, 2012Applicant: NsGene A/SInventors: Philip Kusk, Lars Ulrik Wahlberg, Teit E. Johansen
-
Patent number: 7601518Abstract: The present invention concerns improved methods and compositions for producing a Neublastin polypeptide as well as local delivery of Neublastin to specific regions of the nervous system including the central nervous system and the eye for example by gene therapy. The invention also concerns Neublastin expression constructs which do not encode a pro-region of a Neublastin polypeptide, which expression construct result in increased secretion of bioactive Neublastin. The invention includes the delivery of Neublastin from transduced or transfected cells encapsulated into a macrocapsule with a semipermeable membrane. The invention further concerns mammalian cells capable of producing Neublastin in increased amounts.Type: GrantFiled: June 10, 2004Date of Patent: October 13, 2009Assignee: NsGene A/SInventors: Lars U. Wahlberg, Mette Gronborg, Philip Kusk, Jens Tornoe
-
Publication number: 20090136552Abstract: Disclosed are NsG28, NsG30, NsG32 polypeptides, nucleic acids encoding NsG28, NsG30, NsG32 polypeptides, and antibodies that bind to NsG28, NsG30, NsG32 polypeptides as well as methods of making and using the same.Type: ApplicationFiled: August 1, 2005Publication date: May 28, 2009Inventors: Mette Gronborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Soren Brunak, Lars U. Wahlberg
-
Publication number: 20090087474Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on secreted therapeutic proteins, NsG29 and NsG31. NsG29 and Ns31 are members of a newly identified family of growth factors with a specific cystein pattern and characterised by expression in the nervous system. The secreted growth factors have potential for the treatment of disorders of the nervous system. The invention also relates to bioactive NsG29 and NsG31 polypeptide fragments and the corresponding encoding DNA sequences.Type: ApplicationFiled: January 9, 2006Publication date: April 2, 2009Inventors: Thomas N. Petersen, Nikolaj Blom, Mette Gronborg, Philip Kusk, Soren Brunak, Teit E. Johansen, Lars U. Wahlberg
-
Publication number: 20070275026Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein. NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.Type: ApplicationFiled: March 30, 2005Publication date: November 29, 2007Applicant: NSGENE A/SInventors: Mette Gronborg, Philip Kusk, Nikolaj Blom, Thomas Petersen, Teit Johansen, Soren Brunak, Lars Wahlberg
-
Publication number: 20050089960Abstract: The present invention concerns improved methods and compositions for producing a Neublastin polypeptide as well as local delivery of Neublastin to specific regions of the nervous system including the central nervous system and the eye for example by gene therapy. The invention also concerns Neublastin expression constructs which do not encode a pro-region of a Neublastin polypeptide, which expression construct result in increased secretion of bioactive Neublastin. The invention includes the delivery of Neublastin from transduced or transfected cells encapsulated into a macrocapsule with a semipermeable membrane. The invention further concerns mammalian cells capable of producing Neublastin in increased amounts.Type: ApplicationFiled: June 10, 2004Publication date: April 28, 2005Applicant: NSGENE A/SInventors: Lars Wahlberg, Mette Gronborg, Philip Kusk, Jens Tornoe